Medical specialist in Medical Oncology and Neurology with clinical dedication to brain tumors and neurological complications of cancer.
He has completed his education with a Master's Degree in Translational Oncology and a Diploma in Statistics from the Health Sciences. Subsequently, he coordinated the Multidisciplinary Unit of Neuro-oncology at Hospital 12 de Octubre, where a multidisciplinary translational research group has been formed whose line of fundamental research is the evaluation of new drugs for glioblastoma in preclinical models.
As a result of the preclinical results, Dr Sepúlveda has designed and carried out clinical trials in humans with EGFR, MET and cannabinoid inhibitors. The first results of these clinical trials have already been presented to congresses and others are in the recruitment phase of patients or in the data analysis phase. For the development of independent clinical trials has collaborated with the Spanish Group of Neurooncology (GEINO) of which Dr Sepúlveda is a member of the board of directors since 2011. Additionally he is a member of the BrainTumourGroup of the European Organization for Research and Treatment of Cancer (BTG-EORTC) where he participates actively and is a member of the board of directors of the Spanish Society of Medical Oncology (SEOM).
Dr. Sepúlveda has participated in multiple Phase I, II, III clinical trials where he has participated in the development of diverse molecules from very early stages to randomized trials. From the experimental point of view, the laboratory associated with the Neuro-oncology Unit that coordinates, develops "in vitro", "in vivo" tumor models with xenografts derived from patients and transgenic models, genomic characterization of neoplasms by advanced sequencing techniques and has technology and means for immunohistochemical and immunofluorescence studies in tissues. He has also developed techniques of magnetic separation and flow cytometry in brain tumor splinters.
In the last five years the number of articles has been 35 scientific articles with 17 publications in the first decile of their area and 16 in the first quartile of their area.
The sum of the impact factor of the last five years is 143.8 and the total impact factor according to the ReserarchGate website is 294
During the last two years, Dr Sepúlveda has published in all Neurooncology journals (Neurooncology, Journal of Neurooncology and NeurooncologyPractice) with translational aspects of brain tumors.
Diploma of Advanced Studies in Neurosciences (DEA). Complutense University of Madrid.
2000: Bachelor of Medicine and Surgery. Complutense University of Madrid.
2005: Doctor of Medicine. Title of the thesis: Oligodendroglial tumors, study of clinical, histological and molecular variables. Complutense University of Madrid.
2008: Diploma in Statistics of Health Sciences. Autonomous University of Barcelona.
2009: Master in Molecular Oncology. National Center for Health Institutions Oncological
- European Society of Medical Oncology.
- Spanish Group of Research in Neuro-oncology.
- Spanish Society of Medical Oncology (SEOM).
- European Organization for Research and Treatment of Cancer (EORTC).
- Madrid Society of Neurology.
- Spanish Society of Neurology (SEN).